Amplia Therapeutics Ltd Market Cap ($32.32 Million)
Market Cap & Net Worth: Amplia Therapeutics Ltd (ATX)
Amplia Therapeutics Ltd market cap. Amplia Therapeutics Ltd (AU:ATX) has a market capitalization of $32.32 Million (AU$45.68 Million) as of November 7, 2026. Listed on the AU stock exchange, this Australia-based company holds position #23261 globally and #859 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Amplia Therapeutics Ltd's stock price AU$0.09 by its total outstanding shares 513312014 (513.31 Million). Also see how efficiently does Amplia Therapeutics Ltd generate cash for how efficiently the company converts equity into cash flow.
Amplia Therapeutics Ltd Market Cap History (2015–2026)
Amplia Therapeutics Ltd market cap history from 2015 to 2026. Data shows change from $623.83 Million to $32.32 Million (-23.11% CAGR). Check Amplia Therapeutics Ltd (ATX) stock price for real-time trading data and today's change.
Amplia Therapeutics Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Amplia Therapeutics Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ATX year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
14.40x
Amplia Therapeutics Ltd's market cap is 14.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $93.09 Million | $1.80 Million | -$7.08 Million | 51.77x | N/A |
| 2018 | $46.53 Million | $580.29K | -$4.30 Million | 80.18x | N/A |
| 2019 | $22.26 Million | $50.47K | -$1.87 Million | 441.10x | N/A |
| 2020 | $86.26 Million | $34.23K | -$2.22 Million | 2520.24x | N/A |
| 2021 | $59.93 Million | $1.53 Million | -$2.28 Million | 39.08x | N/A |
| 2022 | $29.06 Million | $1.98 Million | -$3.64 Million | 14.65x | N/A |
| 2023 | $29.06 Million | $1.19 Million | -$6.24 Million | 24.43x | N/A |
| 2024 | $32.32 Million | $4.45 Million | -$4.50 Million | 7.26x | N/A |
| 2025 | $54.48 Million | $3.78 Million | -$6.57 Million | 14.40x | N/A |
Competitor Companies of ATX by Market Capitalization
Companies near Amplia Therapeutics Ltd in the global market cap rankings as of November 7, 2026. Also see ATX total asset value for a full breakdown of the balance sheet.
Key companies related to Amplia Therapeutics Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Amplia Therapeutics Ltd (2015–2026)
Market capitalization of Amplia Therapeutics Ltd from 2015 to today. Between 2015 and today, Amplia Therapeutics Ltd's market cap moved from $623.83 Million to $ 32.32 Million, with a yearly change of -23.11%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | AU$32.32 Million | -40.67% |
| 2025 | AU$54.48 Million | +68.54% |
| 2024 | AU$32.32 Million | +11.25% |
| 2023 | AU$29.06 Million | 0.00% |
| 2022 | AU$29.06 Million | -51.52% |
| 2021 | AU$59.93 Million | -30.53% |
| 2020 | AU$86.26 Million | +287.44% |
| 2019 | AU$22.26 Million | -52.15% |
| 2018 | AU$46.53 Million | -50.02% |
| 2017 | AU$93.09 Million | -97.44% |
| 2016 | AU$3.64 Billion | +483.49% |
| 2015 | AU$623.83 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Amplia Therapeutics Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $32.32 Million USD |
| MoneyControl | $32.32 Million USD |
| MarketWatch | $32.32 Million USD |
| marketcap.company | $32.32 Million USD |
| Reuters | $32.32 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Amplia Therapeutics Ltd
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develo… Read more